The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...

Biocon announced a leadership change. Siddharth Mittal will step down as Managing Director and Chief Executive Officer on March 31. He will...

Biocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...

The Supreme Court granted bail to three individuals involved in the 2024 Pune Porsche accident. The court noted parental responsibility in ...

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canad...

Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Ty...

Biocon Q4 Results: Revenue from operations increased 16% year-on-year (YoY) to Rs 2,947 crore in the January-March 2024 period.

Biocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop...

Anupam Mittal in a recent 'Shark Tank India' episode critiqued young entrepreneur Ha Tade during a pitch for their petrol detector and mete...

Biocon Limited announced that its wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.’s oral solid dosage manufact...

Typically, licensing income tends to be lumpy. When we out-license any of our molecule to our customers, we receive the licensing income an...

He will report to the Chief Executive Officer and Managing Director Siddharth Mittal. Jindal will take over from Indranil Sen who was the i...

Mittal takes over from Arun Chandavarkar who retired as chief executive and joint MD of the company on November 30.

We have a very good track record on GMP compliance. We are taking a digital journey in strengthening our quality system, which will help us...

Buy Bharti Airtel at a price target of Rs 451 and a stop loss at Rs 409 from entry point.

Buy Bharti Airtel Ltd. at a price target of Rs 378.0 and a stop loss at Rs 344.0 from entry point

The apex court, in its April 26 last year interim order, had said that hearing against Mittal and Ruia will remain "postponed" in the trial...